These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 17396743

  • 21. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
    Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M.
    Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
    [Abstract] [Full Text] [Related]

  • 22. Transient perforating folliculitis induced by sorafenib.
    Minami-Hori M, Ishida-Yamamoto A, Komatsu S, Iiduka H.
    J Dermatol; 2010 Sep; 37(9):833-4. PubMed ID: 20883372
    [No Abstract] [Full Text] [Related]

  • 23. [Squamous cell carcinoma in a patient receiving sorafenib].
    Adnot-Desanlis L, Bernard P, Reguiaï Z.
    Ann Dermatol Venereol; 2011 Feb; 138(2):120-3. PubMed ID: 21333823
    [Abstract] [Full Text] [Related]

  • 24. [Hand-foot syndrome and sorafenib].
    Milano G, Mortier L, Digue L, Desmedt E, Ravaud A.
    Bull Cancer; 2009 Feb; 96(2):191-7. PubMed ID: 19258226
    [Abstract] [Full Text] [Related]

  • 25. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
    Autier J, Escudier B, Wechsler J, Spatz A, Robert C.
    Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Severe sorafenib-induced hand-foot skin reaction.
    Cuesta L, Betlloch I, Toledo F, Latorre N, Monteagudo A.
    Dermatol Online J; 2011 May 15; 17(5):14. PubMed ID: 21635836
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
    Hou MM, Hsieh JJ, Chang NJ, Huang HY, Wang HM, Chuang CK, Hsu T, Chang JW.
    Clin Drug Investig; 2010 May 15; 30(11):799-804. PubMed ID: 20635828
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
    Bilaç C, Müezzinoğlu T, Ermertcan AT, Kayhan TC, Temeltaş G, Oztürkcan S, Temiz P.
    Cutan Ocul Toxicol; 2009 May 15; 28(2):90-2. PubMed ID: 19514932
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
    Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C.
    Future Oncol; 2012 Aug 15; 8(8):1051-7. PubMed ID: 22894676
    [Abstract] [Full Text] [Related]

  • 35. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
    Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R.
    Arch Dermatol; 2008 Jun 15; 144(6):779-82. PubMed ID: 18559769
    [Abstract] [Full Text] [Related]

  • 36. Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
    Degen A, Satzger I, Voelker B, Kapp A, Hauschild A, Gutzmer R.
    Dermatology; 2010 Jun 15; 221(3):193-6. PubMed ID: 20720388
    [Abstract] [Full Text] [Related]

  • 37. [Sorafenib-induced multiple eruptive keratoacanthomas].
    Jantzem H, Dupre-Goetghebeur D, Spindler P, Merrer J.
    Ann Dermatol Venereol; 2009 Dec 15; 136(12):894-7. PubMed ID: 20004316
    [Abstract] [Full Text] [Related]

  • 38. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
    Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ.
    J Clin Oncol; 2006 Jun 01; 24(16):2505-12. PubMed ID: 16636341
    [Abstract] [Full Text] [Related]

  • 39. Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
    Rini BI.
    Clin Adv Hematol Oncol; 2011 Apr 01; 9(4):337-8. PubMed ID: 21558996
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.